Abstract
Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have